Russia’s “State Institute of Drugs and Good Practices” (FSI “SID & GP”) and the Center for Food and Drug Inspection of China’s National Medical Products Administration (CFDI) have signed a cooperation agreement in Beijing
The agreement aims to establish long‑term cooperation on pharmaceutical inspections for compliance with Good Manufacturing Practice (GMP) standards.
The parties will cooperate on pharmaceutical regulation, particularly on Good Manufacturing Practice, including joint training programmes, advisory activities and information exchange within the scope of their respective mandates.
The agreement was signed by Vladislav Shestakov, director of SID & GP, and Li Fang, director‑general of CFDI.
“This agreement is a step towards long‑term Russian‑Chinese partnership in pharmaceutical regulation and GMP. It gives our interaction a systemic, institutional character and raises it to a qualitatively new level. Active cooperation between our experts is a solid foundation for building trust between the regulatory authorities of Russia and China,” said Vladislav Shestakov.
Earlier, FSI “SID & GP” signed a memorandum of understanding with Algeria’s National Agency for Pharmaceutical Products (ANPP) and with the Saudi Food and Drug Authority (SFDA) of the Kingdom of Saudi Arabia.
